Anti-VEGFs superior to laser photocoagulation

Article

According to recently published data, anti-VEGF therapy is superior to laser photocoagulation for the treatment of moderate-to-severe visual impairment caused by diabetic macular oedema (DME).

According to recently published data, anti-VEGF therapy is superior to laser photocoagulation for the treatment of moderate-to-severe visual impairment caused by diabetic macular oedema (DME).

The study, performed by Dr Tian Yin Wong et al. (Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore), was a perspective review of literature on DME treatment modalities. This review included studies published between January 1985 and July 2013.

In this review, the authors found that although laser photocoagulation has been the mainstay treatment for DME for nearly 30 years, more recently there has been increasing evidence demonstrating superior results with anti-VEGF therapy. Also, from large phase II and III trials for ranibizumab, the authors found that visual improvement and safety profiles were favourable towards the anti-VEGF therapy over laser photocoagulation for up to 3 years. Patients were also more likely to experience visual loss with laser treatment.

There were limited studies for other anti-VEGF therapies, such as bevacizumab and aflibercept in DME, however, even in these limited cases the results favoured the anti-VEGF therapeutic option.

For more detailed information please visit the American Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.